Hologic's strong Breast Health segment performance is expected to be a key driver for its fiscal first-quarter 2024 earnings. Despite potential challenges in the Diagnostics and Medical Aesthetics divisions, growth in Breast Health, particularly from the Panther platform, is anticipated to support overall revenue. The company is set to release its Q1 2024 results on January 31, 2024.

豪洛捷

<p>霍洛捷（Hologic）強勁的乳腺健康部門表現預計將成為其 2024 財年第一季度收益的關鍵驅動力。儘管在診斷和醫療美容部門可能面臨挑戰，但乳腺健康的增長，特別是來自 Panther 平台的增長，預計將支持整體收入。該公司計劃於 2024 年 1 月 31 日發佈其 2024 年第一季度的業績</p>

乳腺健康業務的表現可能有助於提升豪洛捷的第一季度收益